Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Share-based Compensation (2022 - 2025)

Historic Share-based Compensation for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to $4.8 million.

  • Zentalis Pharmaceuticals' Share-based Compensation fell 5340.67% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.0 million, marking a year-over-year decrease of 165.31%. This contributed to the annual value of $67.3 million for FY2024, which is 2270.44% up from last year.
  • Zentalis Pharmaceuticals' Share-based Compensation amounted to $4.8 million in Q3 2025, which was down 5340.67% from $6.3 million recorded in Q2 2025.
  • In the past 5 years, Zentalis Pharmaceuticals' Share-based Compensation registered a high of $31.4 million during Q4 2024, and its lowest value of $4.8 million during Q3 2025.
  • Its 4-year average for Share-based Compensation is $12.4 million, with a median of $12.7 million in 2024.
  • Per our database at Business Quant, Zentalis Pharmaceuticals' Share-based Compensation surged by 12595.82% in 2024 and then crashed by 5340.67% in 2025.
  • Zentalis Pharmaceuticals' Share-based Compensation (Quarter) stood at $9.6 million in 2022, then soared by 44.4% to $13.9 million in 2023, then skyrocketed by 125.96% to $31.4 million in 2024, then crashed by 84.61% to $4.8 million in 2025.
  • Its last three reported values are $4.8 million in Q3 2025, $6.3 million for Q2 2025, and $6.5 million during Q1 2025.